HWM
XENT

HighMark Wealth Management’s Intersect ENT, Inc XENT Stock Holding History

HighMark Wealth Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,715
Closed -$244K – 559
2022
Q1 		$244K Hold
8,715
– – 0.16% 46
2021
Q4 		$238K Sell
8,715
-1,000
-10% -$27.1K 0.15% 50
2021
Q3 		$264K Buy
9,715
+140
+1% +$3.46K 0.19% 42
2021
Q2 		$164K Buy
9,575
+7,828
+448% +$147K 0.12% 54
2021
Q1 		$36K Sell
1,747
-129
-7% -$2.98K 0.03% 125
2020
Q4 		$43K Sell
1,876
-4,537
-71% -$86.4K 0.04% 103
2020
Q3 		$105K Buy
6,413
+4,317
+206% +$78.2K 0.09% 66
2020
Q2 		$28K Buy
2,096
+1,496
+249% +$17.4K 0.03% 111
2020
Q1 		$7K Hold
600
– – 0.01% 194
2019
Q4 		$14K Buy
+600
New +$12.2K 0.01% 166

HighMark Wealth Management's XENT Position: Q2 2022 in Review

HighMark Wealth Management sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 8,715 shares — an estimated $244K sold.

HighMark Wealth Management first reported a position in XENT in Q4 2019 and held it in 10 quarters. The position peaked at $264K in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • HighMark Wealth Management reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • HighMark Wealth Management sold 8,715 Intersect ENT, Inc shares in Q2 2022, an estimated $244K.
  • HighMark Wealth Management first reported a position in Intersect ENT, Inc in Q4 2019 and held it in 10 quarters.
  • HighMark Wealth Management's Intersect ENT, Inc position peaked at $264K in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on HighMark Wealth Management's 13F filing for Q2 2022, filed 19 Jul 2022.